Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetic Study in Healthy Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lycopene in Healthy Male Participants

NCT00450957
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Prostate Cancer
Interventions
lycopene, pharmacological study
Dietary Supplement · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge

NCT01887847
View directory record Official record
Conditions
Nicotine Pharmacokinetic Study
Interventions
Nicotine (Pharmaceutical Productions Inc.)
Drug
Lead sponsor
Pharmaceutical Productions Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

NCT05988021
View directory record Official record
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
CCX168
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

NCT01235338
View directory record Official record
Conditions
Healthy
Interventions
LDX + Venlafaxine XR, Venlafaxine XR + LDX
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

NCT01632917
View directory record Official record
Conditions
Healthy
Interventions
ATX-101 - U.S., ATX-101 - EU
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

NCT00284908
View directory record Official record
Conditions
Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions
S-Tenatoprazole-Na (STU-Na)
Drug
Lead sponsor
STEBA France
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2008 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

NCT05154136
View directory record Official record
Conditions
Healthy Participants
Interventions
Etrumadenant, Itraconazole
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations

NCT00688857
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Diazoxide choline
Drug
Lead sponsor
Essentialis, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

NCT07456800
View directory record Official record
Conditions
Pharmacokinetic Analysis
Interventions
Deupirfenidone, Pirfenidone (PFD), Placebo
Drug
Lead sponsor
PureTech
Industry
Eligibility
60 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Lake Mary, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects

NCT00772265
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin N, Novolin N
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica

NCT02753101
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Sciatica
Interventions
[18F]-FTC-146
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

NCT03926819
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
HBI-002
Drug
Lead sponsor
Hillhurst Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

NCT01462851
View directory record Official record
Conditions
Healthy
Interventions
PF-05297909 25 mg, PF-05297909 100 mg, PF-05297909 250 mg, PF-05297909 525 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

NCT02634437
View directory record Official record
Conditions
Renal Function
Interventions
Ulipristal acetate
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

NCT06467201
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

NCT03836729
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir alafenamide/emtricitabine, GSK3640254
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

NCT04425902
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 200 mg, Caffeine 200 mg, Metoprolol 100 mg, Montelukast 10 mg, Flurbiprofen 100 mg, Omeprazole 40 mg, Midazolam 5 mg (2.5 mL), Digoxin 0.25 mg, Pravastatin 40 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

NCT01464450
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability, Healthy Participants
Interventions
Rivaroxaban
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

NCT07455825
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

NCT05999513
View directory record Official record
Conditions
Healthy Participants
Interventions
casdatifan
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers

NCT01080820
View directory record Official record
Conditions
Healthy
Interventions
CMX157, Placebo, Viread
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 3, 2011 · Synced Jun 26, 2026, 1:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

NCT00532116
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg, EMSAM (Selegiline Transdermal System) 12mg
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 18, 2007 · Synced Jun 26, 2026, 1:37 PM EDT